Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. - Wikidata - awgldk - TriplyDB

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

http://www.wikidata.org/entity/Q36646261

about

Mechanism of action of lenalidomide in hematological malignancies β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide Thalidomide analogues as anticancer drugs Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Early experience with novel immunomodulators for cancer treatment Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer Neovascular niche for human myeloma cells in immunodeficient mouse bone Emerging drugs for chronic lymphocytic leukaemia.Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Immunomodulatory drugs in myelodysplastic syndromes.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Phase I study of oral lenalidomide in patients with refractory metastatic cancer Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates Angiogenesis inhibition in prostate cancer: current uses and future promises.Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients.Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Chemical 'Jekyll and Hyde's: small-molecule inhibitors of developmental signaling pathways Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Modest activity of pomalidomide in patients with myelofibrosis and significant anemia Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Treatment of pediatric refractory Crohn's disease with thalidomide.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Lenalidomide in the treatment of multiple myeloma: a review.Recent developments in antiangiogenic therapy.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Expanding role of lenalidomide in hematologic malignancies

P2860

Q21198872-33FB771D-5D6B-4F3A-963D-9C53C43935B4 Q24306884-3BF47917-C288-4A48-AE74-67A0B941D7DD Q24605861-B955A666-F876-40FE-9BCF-B49FF950C208 Q24614147-7B9C80B6-67BD-494F-9584-FF22E9F0C740 Q24670383-906D1A60-8C74-49AA-962B-E3AE2F281064 Q28192646-E787AE82-64A9-4D0E-A3A0-91879A0F9591 Q28241744-1752FB09-F0C5-4594-B4C0-B3E9478F994C Q28534997-2C31C83F-2EC9-4078-B768-C51E8614EC5F Q28732210-B20D546C-DD88-4CA2-AB6E-37DC78725C2F Q30353154-6CC6B38C-5743-4937-B0D2-ACB901FD4FF2 Q33238514-01CFE87D-EACD-466A-88C9-8F87385F04BD Q33322921-540FB197-D491-4769-985B-9BEAE22A30A0 Q33371622-D6E2F676-9D84-493E-8544-D7C343414596 Q33413142-331EA8A9-73EA-4AD3-B4C3-B806C6179680 Q33413210-290C4377-EB13-4E77-9A38-F5B3D15DBF55 Q33420263-5E0F1AC2-EB0D-410B-AA51-318F6C03E334 Q33429608-18351182-DEB4-4E59-979D-784FA1B207F0 Q33600521-14F2A055-EB99-40AF-A782-97BC5A5C90A2 Q33627051-BABBC887-9375-42D4-8692-E2DB7774C9EF Q33639796-CB236BE2-1DDC-49F9-8729-3C990959ED97 Q33652297-0144DEF6-844A-482B-AD08-A43AE30A1455 Q33689002-B526C228-DAE0-40A6-BAC8-DE26ECC36C3F Q33760451-0E58BAAC-FE05-4FB8-A049-878A2F2F4DEC Q33813750-54F380D3-3060-444F-9705-F01902311D78 Q33820610-489E9D10-E80B-4658-AEA0-4FB4123C5520 Q33843008-28F411A2-14F9-4880-BA26-0085846B5362 Q33847401-17702383-AD01-40FB-AE5E-66762CA26EE2 Q33874179-3D2C9968-579F-436C-9460-BDF14A6E3492 Q33877283-7E3FF72A-334A-4E29-9956-25E20664DB81 Q33960866-274BCAD6-9D0F-471B-AC6D-B6C11CA40B49 Q34220013-C5B8DE67-07AF-4D56-8998-37FE7F91E938 Q34253548-E670A4E3-55EA-412C-8A23-ACBBBFA24DAB Q34512203-474BA11A-7B81-4B81-843E-93DA8B1C622A Q34666858-7829024A-DBDB-452F-B86D-86FC6379C5A2 Q34744824-C92D07A3-06C2-4340-AC18-6B481A7B9A15 Q34775475-263DB3BE-1925-4FEF-9092-2078C7D3DD1F Q34775515-1CDF3EAC-5343-486C-8E69-BB4A32CAB3F7 Q35040867-86AEBEEE-D3C9-4088-AFAB-481D042005C1 Q35171777-8B01962E-65E4-480B-841B-B5AFE12DC00E Q35592305-6C1340C4-D8D2-4A58-B48D-2C7F32F8A3B9

P2860

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

http://www.wikidata.org/entity/Q36646261

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@ast

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@en

type

label

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@ast

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@en

prefLabel

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@ast

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@en

P1433

Q36646261-0961CC52-E95C-4CB7-8551-CCE1C62F031C

P1476

Q36646261-85C8CC49-8B3C-410C-BA99-F095A627D9B1

P2093

Q36646261-040C0169-F8C0-42AF-8A4F-3AE203287B76

Q36646261-0F305B72-06F9-4BDD-9C58-10D4835CD3AB

Q36646261-2C21BBBA-11B7-48D9-B16C-D82FE622C6BF

Q36646261-408D9049-1E1B-4787-9A30-9EC10AD79A67

Q36646261-54E8FD39-75E5-49FC-AFD1-E0DD371CA549

Q36646261-75CF3C0D-6985-4604-92A7-9DDBA3B3AF85

Q36646261-9D6271B0-7A4A-46A1-9C0E-AF933E63B725

Q36646261-C3151A10-3559-4115-9BA0-FFB40221C09C

P2860

Q36646261-349C06DC-5687-4D8B-A2A9-F6E2386ABC02

Q36646261-3B2E35F0-E4D2-41B5-AB93-C9693172A84F

Q36646261-3B30336C-824B-42AA-9242-25E3D728A92F

Q36646261-4382FA06-64EA-4DA7-97E6-8525663F703E

Q36646261-57E74BA4-66CF-42CA-AE81-545F93ACB70E

Q36646261-5E028724-365D-4EBE-889D-B6D1A41F4DAF

Q36646261-67EB57AB-6F58-4D8F-84A4-49DFAF1E687B

Q36646261-681E17C8-7D2A-4CC2-9177-ECAF31AC8060

Q36646261-6859719A-0B9B-464B-9C61-CBF49D0CE2B1

Q36646261-6B6518DD-59CD-4B44-8D17-CCF78A64B2AC

P2888

Q36646261-2392D609-D365-47C7-867F-CD02A4EB7216

P304

Q36646261-0127039B-E466-418C-A574-744027BA61E5

P31

Q36646261-22525516-8852-4902-A562-4DB026A85CC2

P356

Q36646261-8636081C-F183-4E04-9FDF-4565F1405812

P407

Q36646261-E88CE3FC-F1FB-4CD8-B13D-5854471EE322

P433

Q36646261-4DB6F77C-A4CF-465F-B342-5487381B6361

P478

Q36646261-E6F37AE4-2460-4466-8724-386A012101DB

P577

Q36646261-7B0E4225-1D5E-4AD5-9238-42EC5D488C9A

P5875

Q36646261-8D1AEC17-60DF-4327-8F6E-ABE8E60A180E

P698

Q36646261-E2B33042-88E8-4EF9-9C59-D556780BD472

P921

Q36646261-4FB2B1A6-CD32-4926-9A6E-FAB1D6EE6C67

P932

Q36646261-5F2774B5-5889-40D3-B1A0-92D2F7E5A55B

P356

P1433

British Journal of Cancer

P1476

Novel thalidomide analogues di ...... y of immunomodulatory effects.

@en

P2093

A G Dalgleish

http://www.w3.org/2001/XMLSchema#string

C D Macdonald

http://www.w3.org/2001/XMLSchema#string

D Stirling

http://www.w3.org/2001/XMLSchema#string

G W Muller

http://www.w3.org/2001/XMLSchema#string

H-W Man

http://www.w3.org/2001/XMLSchema#string

J B Marriott

http://www.w3.org/2001/XMLSchema#string

K Dredge

http://www.w3.org/2001/XMLSchema#string

R Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Angiogenesis in cancer and other diseases

Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro

Antitumor activity of thalidomide in refractory multiple myeloma.

Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Immunotherapeutic and antitumour potential of thalidomide analogues.

Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.

Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.

Permanent cell line expressing human factor VIII-related antigen established by hybridization.

IL-12 regulates VEGF and MMPs in a murine breast cancer model.

P2888

P304

1166-1172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6600607

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11062038

http://www.w3.org/2001/XMLSchema#string

P698

12402158

http://www.w3.org/2001/XMLSchema#string

P921

P932

2376196

http://www.w3.org/2001/XMLSchema#string